Certara buys CRO Synchrogenix as regulatory writing sees more outsourcing

By Zachary Brennan

- Last updated on GMT

Certara buys Synchrogenix as regulatory writing sees more outsourcing
Consultancy and drug developer Certara has acquired specialty contract research organization (CRO) Synchrogenix Information Strategies, which offers regulatory writing and related services to biopharma and medical device companies worldwide. 

Financial details of the acquisition were not disclosed.The acquisition comes as the market for outsourced regulatory writing is seeing more growth, Certara spokeswoman Lisa Osborne told Outsourcing-pharma.com

The regulatory writing market is on the upswing as more biopharma and medical device companies are outsourcing these services​,” Osborne said. “There’s a shortage of employees with the requisite background as it’s a highly specialized niche market.”

The acquisition will combine Delaware-based Synchrogenix, which is the largest independent regulatory-writing CRO in the world, with Certara, which offers scientific informatics and analytics, including molecular modeling, population-based simulations, pharmacokinetic analyses and clinical trial simulations.

Certara has more than 225 employees located at offices in the US, UK, Canada, and Japan.

Synchrogenix has more than 50 permanent regulatory writers and editors on staff, located in seven offices in North America, Europe, and Asia. The company provides pre-clinical, clinical, CMC and drug safety writing, and global regulatory submission services.

The acquisition occurred now as Certara was looking to expand its small regulatory writing team in Montreal more globally, Osborne said. The two companies also have overlapping clients, but they’re dealing with different individuals in the groups. The objective is to synchronize those discussions into a more continuous process for the client, she said.

 “We were attracted to Synchrogenix by the quality of its work, its outstanding reputation and the global network of regulatory experts that it has developed. By combining the most sophisticated regulatory professional organization with the world’s leading computational drug development capabilities, we believe that Certara can continue to enable our clients to improve the pace of efficacious drug development for the benefit of patients around the world​,” Donald Deieso, Chairman of Certara, added.

Related news

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

The Complete Guide to eRegulatory and eSource

The Complete Guide to eRegulatory and eSource

Content provided by Florence Healthcare | 01-Apr-2023 | Insight Guide

Shifting to eRegulatory and eSource workflows is a requirement for clinical trial sites to continue to scale and grow their studies. This guide is designed...

Follow us

Products

View more

Webinars